Chiome Bioscience Inc.
4583.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | ¥8,981,498 | ¥10,121,057 | ¥9,798,966 | ¥17,163,015 |
| - Cash | ¥1,005,747 | ¥1,474,952 | ¥1,818,759 | ¥2,063,280 |
| + Debt | ¥79,400 | ¥260,500 | ¥281,500 | ¥281,500 |
| Enterprise Value | ¥8,055,151 | ¥8,906,605 | ¥8,261,707 | ¥15,381,235 |
| Revenue | ¥118,019 | ¥113,097 | ¥138,699 | ¥358,179 |
| % Growth | 4.4% | -18.5% | -61.3% | – |
| Gross Profit | ¥65,301 | ¥58,223 | ¥80,643 | ¥213,202 |
| % Margin | 55.3% | 51.5% | 58.1% | 59.5% |
| EBITDA | -¥256,957 | -¥272,380 | -¥264,351 | -¥109,619 |
| % Margin | -217.7% | -240.8% | -190.6% | -30.6% |
| Net Income | -¥259,963 | -¥274,224 | -¥266,066 | -¥105,275 |
| % Margin | -220.3% | -242.5% | -191.8% | -29.4% |
| EPS Diluted | -3.82 | -4.04 | -3.94 | -1.65 |
| % Growth | 5.4% | -2.5% | -138.8% | – |
| Operating Cash Flow | – | ¥0 | ¥0 | ¥0 |
| Capital Expenditures | – | ¥0 | ¥0 | ¥0 |
| Free Cash Flow | – | ¥0 | ¥0 | ¥0 |